Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “sell” rating restated by equities researchers at Wells Fargo & Company in a research report issued to clients and investors on Monday.

Other equities analysts also recently issued reports about the company. J P Morgan Chase & Co set a $10.00 price target on Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Monday, July 17th. HC Wainwright reaffirmed a “hold” rating and issued a $17.00 price target on shares of Valeant Pharmaceuticals International in a report on Wednesday, October 4th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $23.00 price target on shares of Valeant Pharmaceuticals International in a report on Tuesday, August 29th. Deutsche Bank AG set a $19.00 price target on Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Monday, August 21st. Finally, Vetr downgraded Valeant Pharmaceuticals International from a “strong-buy” rating to a “hold” rating and set a $14.26 price target for the company. in a report on Friday, October 13th. Five equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $17.22.

Valeant Pharmaceuticals International (NYSE:VRX) opened at $14.60 on Monday. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $18.71. The company has a market capitalization of $5,361.34, a PE ratio of 2.50, a PEG ratio of 0.43 and a beta of -0.40. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26.

COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International, Inc. (VRX) Earns Sell Rating from Wells Fargo & Company” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/valeant-pharmaceuticals-international-inc-vrx-earns-sell-rating-from-wells-fargo-company/1701946.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were purchased at an average price of $14.33 per share, with a total value of $143,300.00. Following the completion of the acquisition, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.87% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Riggs Asset Managment Co. Inc. grew its holdings in Valeant Pharmaceuticals International by 118.2% during the third quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after acquiring an additional 4,512 shares during the period. Financial Architects Inc grew its holdings in Valeant Pharmaceuticals International by 10.5% in the second quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock valued at $183,000 after purchasing an additional 1,000 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Valeant Pharmaceuticals International by 33.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 2,763 shares during the last quarter. Cetera Investment Advisers acquired a new stake in Valeant Pharmaceuticals International in the second quarter valued at $192,000. Finally, IPG Investment Advisors LLC acquired a new stake in Valeant Pharmaceuticals International in the second quarter valued at $203,000. 46.61% of the stock is currently owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.